Neuroscientific Biopharmaceuticals Ltd (NSB) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.029x

Based on the latest financial reports, Neuroscientific Biopharmaceuticals Ltd (NSB) has a cash flow conversion efficiency ratio of -0.029x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-480.55K ≈ $-340.02K USD) by net assets (AU$16.81 Million ≈ $11.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Neuroscientific Biopharmaceuticals Ltd stock valuation for the company's overall valuation and market capitalisation.

Neuroscientific Biopharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Neuroscientific Biopharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Neuroscientific Biopharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Neuroscientific Biopharmaceuticals Ltd ranked by their cash flow conversion efficiency. Explore Neuroscientific Biopharmaceuticals Ltd earnings quality ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Donegal Investment Group PLC IR:DQ7A	-0.234x
FACILITIES BY ADF LS-01 F:ZC8	N/A
HWH International Inc NASDAQ:HWH	0.171x
Phapros Tbk PT JK:PEHA	0.094x
Painchek Ltd AU:PCK	2.987x
Knightscope Inc NASDAQ:KSCP	-0.382x
Millennium Pharmacon International JK:SDPC	-0.062x
Airo Lam limited NSE:AIROLAM	0.083x

Annual Cash Flow Conversion Efficiency for Neuroscientific Biopharmaceuticals Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Neuroscientific Biopharmaceuticals Ltd from 2016 to 2025. View current stock price of Neuroscientific Biopharmaceuticals Ltd for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$16.81 Million ≈ $11.90 Million	AU$-941.33K ≈ $-666.05K	-0.056x	-776.94%
2024-06-30	AU$5.35 Million ≈ $3.79 Million	AU$44.25K ≈ $31.31K	0.008x	+101.68%
2023-06-30	AU$4.69 Million ≈ $3.32 Million	AU$-2.30 Million ≈ $-1.63 Million	-0.491x	+60.97%
2022-06-30	AU$5.52 Million ≈ $3.91 Million	AU$-6.94 Million ≈ $-4.91 Million	-1.258x	-606.05%
2021-06-30	AU$14.60 Million ≈ $10.33 Million	AU$-2.60 Million ≈ $-1.84 Million	-0.178x	+71.50%
2020-06-30	AU$3.65 Million ≈ $2.58 Million	AU$-2.28 Million ≈ $-1.61 Million	-0.625x	-124.79%
2019-06-30	AU$5.06 Million ≈ $3.58 Million	AU$-1.41 Million ≈ $-995.83K	-0.278x	+59.09%
2018-06-30	AU$732.52K ≈ $518.30K	AU$-497.91K ≈ $-352.30K	-0.680x	-95.36%
2017-06-30	AU$535.79K ≈ $379.10K	AU$-186.42K ≈ $-131.90K	-0.348x	+50.65%
2016-06-30	AU$124.47K ≈ $88.07K	AU$-87.76K ≈ $-62.09K	-0.705x	--

About Neuroscientific Biopharmaceuticals Ltd

AU:NSB Australia Biotechnology

Market Cap

$14.35 Million

AU$20.29 Million AUD

Market Cap Rank

#26192 Global

#1173 in Australia

Share Price

AU$0.06

Change (1 day)

+1.67%

52-Week Range

AU$0.06 - AU$0.17

All Time High

AU$0.52